相似文献
1
Chemical Modification of Linkers Provides Stable Linker-Payloads for the Generation of Antibody-Drug Conjugates.
ACS Med Chem Lett. 2020 Sep 22;11(11):2190-2194. doi: 10.1021/acsmedchemlett.0c00325. eCollection 2020 Nov 12.
2
Self-Immolative Carbamate Linkers for CD19-Budesonide Antibody-Drug Conjugates.
Bioconjug Chem. 2023 Oct 18;34(10):1835-1850. doi: 10.1021/acs.bioconjchem.3c00354. Epub 2023 Oct 3.
3
Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design.
Mol Cancer Ther. 2016 May;15(5):958-70. doi: 10.1158/1535-7163.MCT-15-1004. Epub 2016 Mar 4.
4
[Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)].
Yakugaku Zasshi. 2019;139(2):209-219. doi: 10.1248/yakushi.18-00169-3.
5
The Analysis of Key Factors Related to ADCs Structural Design.
Front Pharmacol. 2019 Apr 24;10:373. doi: 10.3389/fphar.2019.00373. eCollection 2019.
6
Where Did the Linker-Payload Go? A Quantitative Investigation on the Destination of the Released Linker-Payload from an Antibody-Drug Conjugate with a Maleimide Linker in Plasma.
Anal Chem. 2016 May 3;88(9):4979-86. doi: 10.1021/acs.analchem.6b00976. Epub 2016 Apr 21.
7
Lysosomal-Cleavable Peptide Linkers in Antibody-Drug Conjugates.
Biomedicines. 2023 Nov 16;11(11):3080. doi: 10.3390/biomedicines11113080.
8
Linker Design Impacts Antibody-Drug Conjugate Pharmacokinetics and Efficacy Modulating the Stability and Payload Release Efficiency.
Front Pharmacol. 2021 Jun 23;12:687926. doi: 10.3389/fphar.2021.687926. eCollection 2021.
9
Polyethylene glycol-based linkers as hydrophilicity reservoir for antibody-drug conjugates.
J Control Release. 2021 Sep 10;337:431-447. doi: 10.1016/j.jconrel.2021.07.041. Epub 2021 Jul 27.
10
Modulating Antibody-Drug Conjugate Payload Metabolism by Conjugation Site and Linker Modification.
Bioconjug Chem. 2018 Apr 18;29(4):1155-1167. doi: 10.1021/acs.bioconjchem.7b00785. Epub 2018 Mar 13.
引用本文的文献
1
Advancements in antibody-drug conjugates as cancer therapeutics.
J Natl Cancer Cent. 2025 Apr 19;5(4):362-378. doi: 10.1016/j.jncc.2025.01.007. eCollection 2025 Aug.
2
Second Generation Tiancimycin-Based Antibody-Drug Conjugates Enabled by Highly Efficient Semi-synthetic Approach Specifically Targeting B-Cell Malignancies.
JACS Au. 2025 Jul 1;5(7):3171-3181. doi: 10.1021/jacsau.5c00353. eCollection 2025 Jul 28.
3
The Impact of Conjugation Mode and Site on Tubulysin Antibody-Drug-Conjugate Efficacy and Stability.
ChemistryOpen. 2025 May 28:e2400522. doi: 10.1002/open.202400522.
4
Discovery and Characterization of a First-in-Class LIV1-TLR7/8 Immunomodulatory Conjugate with Robust Myeloid Activation and Antitumor Activity.
J Med Chem. 2025 Jun 12;68(11):11322-11339. doi: 10.1021/acs.jmedchem.5c00264. Epub 2025 May 24.
5
Targeted Delivery of TLR7 Agonists to the Tumor Microenvironment Enhances Tumor Immunity via Activation of Tumor-Resident Myeloid Cells.
Bioconjug Chem. 2025 Mar 19;36(3):437-448. doi: 10.1021/acs.bioconjchem.4c00534. Epub 2025 Feb 13.
6
Exo-Cleavable Linkers: Enhanced Stability and Therapeutic Efficacy in Antibody-Drug Conjugates.
J Med Chem. 2024 Oct 24;67(20):18124-18138. doi: 10.1021/acs.jmedchem.4c01251. Epub 2024 Oct 15.
7
Lysosomal-Cleavable Peptide Linkers in Antibody-Drug Conjugates.
Biomedicines. 2023 Nov 16;11(11):3080. doi: 10.3390/biomedicines11113080.
8
Application of a Biocatalytic Strategy for the Preparation of Tiancimycin-Based Antibody-Drug Conjugates Revealing Key Insights into Structure-Activity Relationships.
J Med Chem. 2023 Jan 26;66(2):1562-1573. doi: 10.1021/acs.jmedchem.2c01771. Epub 2023 Jan 4.
9
Functional Characterization of Cytochrome P450 Hydroxylase YpmL in Yangpumicin A Biosynthesis and Its Application for Anthraquinone-Fused Enediyne Structural Diversification.
Org Lett. 2022 Feb 11;24(5):1219-1223. doi: 10.1021/acs.orglett.2c00009. Epub 2022 Jan 27.
10
Cytochrome P450 Hydroxylase TnmL Catalyzing Sequential Hydroxylation with an Additional Proofreading Activity in Tiancimycin Biosynthesis.
ACS Chem Biol. 2021 Jul 16;16(7):1172-1178. doi: 10.1021/acschembio.1c00365. Epub 2021 Jun 17.
本文引用的文献
1
Antibody Conjugates-Recent Advances and Future Innovations.
Antibodies (Basel). 2020 Jan 8;9(1):2. doi: 10.3390/antib9010002.
2
Design, synthesis and biological evaluation of phenol-linked uncialamycin antibody-drug conjugates.
Bioorg Med Chem Lett. 2020 Jan 1;30(1):126782. doi: 10.1016/j.bmcl.2019.126782. Epub 2019 Nov 9.
3
Unraveling the Interaction between Carboxylesterase 1c and the Antibody-Drug Conjugate SYD985: Improved Translational PK/PD by Using Ces1c Knockout Mice.
Mol Cancer Ther. 2018 Nov;17(11):2389-2398. doi: 10.1158/1535-7163.MCT-18-0329. Epub 2018 Aug 9.
4
Glutamic acid-valine-citrulline linkers ensure stability and efficacy of antibody-drug conjugates in mice.
Nat Commun. 2018 Jun 28;9(1):2512. doi: 10.1038/s41467-018-04982-3.
5
High-Throughput Cysteine Scanning To Identify Stable Antibody Conjugation Sites for Maleimide- and Disulfide-Based Linkers.
Bioconjug Chem. 2018 Feb 21;29(2):473-485. doi: 10.1021/acs.bioconjchem.7b00791. Epub 2018 Feb 9.
6
Protease-Cleavable Linkers Modulate the Anticancer Activity of Noninternalizing Antibody-Drug Conjugates.
Bioconjug Chem. 2017 Jul 19;28(7):1826-1833. doi: 10.1021/acs.bioconjchem.7b00304. Epub 2017 Jul 6.
7
Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design.
Mol Cancer Ther. 2016 May;15(5):958-70. doi: 10.1158/1535-7163.MCT-15-1004. Epub 2016 Mar 4.
8
Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading.
Nat Biotechnol. 2015 Jul;33(7):694-6. doi: 10.1038/nbt.3274.
9
Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index.
Nat Biotechnol. 2015 Jul;33(7):733-5. doi: 10.1038/nbt.3212. Epub 2015 Jun 15.
10
Current ADC Linker Chemistry.
Pharm Res. 2015 Nov;32(11):3526-40. doi: 10.1007/s11095-015-1657-7. Epub 2015 Mar 11.
Zotero 插件